Dose Finding in the Clinical Development of 60 US Food and Drug Administration–Approved Drugs Compared With Learning vs. Confirming Recommendations-Reference-Cited by-同舟云学术

Dose Finding in the Clinical Development of 60 US Food and Drug Administration–Approved Drugs Compared With Learning vs. Confirming Recommendations

Published:2019-06-29 Issue:5 Volume:12 Page:481-489
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clin Transl Sci

Author:

Lyauk Yassine Kamal¹²,Jonker Daniël Martijn¹,Lund Trine Meldgaard²

Affiliation:

1. Translational MedicineFerring Pharmaceuticals A/S Copenhagen Denmark

2. Department of Drug Design and PharmacologyUniversity of Copenhagen Copenhagen Denmark

Funder

Ferring

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cts.12641

Reference34 articles.

1. Scientific and Regulatory Reasons for Delay and Denial of FDA Approval of Initial Applications for New Drugs, 2000-2012

2. Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999

3. Duong A.H.Postmarketing drug dosage changes of 413 FDA‐approved new molecular entities 2000–2014. Drug Information Association 2017 Chicago IL. Abstract M‐08 . Accessed June 11 2018.

4. Learning versus confirming in clinical drug development*

5. More efficient clinical trials through use of scientific model-based statistical tests

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase 3;Fundamentals of Drug Development;2022-08-11

2. Confirmatory efficacy testing for individual dose–placebo comparisons using serial gatekeeping procedure in dose‐finding trials with multiple comparison procedures–modeling;Pharmaceutical Statistics;2022-06-16

3. Effect of physical therapy on the flexibility of the infrapatellar fat pad: A single-blind randomised controlled trial;PLOS ONE;2022-03-17

4. Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer;Drugs;2021-12-11

5. Moving Beyond 3+3: The Future of Clinical Trial Design;American Society of Clinical Oncology Educational Book;2021-06